Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk's stock dropped by more than 4% following disappointing results from a Phase 2a trial of its obesity pill, Monlunabant. The experimental drug, acquired through Inversago Pharmaceuticals, ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

For significant weight loss, Zepbound may be the better option. If you have Type 2 diabetes and are looking for a dual ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...